Reference #2 CF

Abstract

Rare diseases affect 400 million individuals worldwide, causing significant morbidity and mortality. Cystic fibrosis (CF) is a genetic, autosomal recessive, multisystemic, life-limiting disease. Despite advancements in understanding CF, treatment remains challenging, with a historical focus on symptom management. The discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene has facilitated the identification of potential therapies targeting the dysfunctional CFTR protein. Recent years have seen the emergence of promising CFTR modulators aimed at restoring CFTR function, improving the lives of many CF patients. Ongoing research aims to develop even more effective targeted therapies.

Introduction

Cystic fibrosis (CF) has transitioned from being a fatal disease of unknown cause to a comprehensively understood condition at the molecular level. The absence of CFTR leads to impaired airway hydration, mucociliary clearance suppression, and bronchial destruction due to pathogenic proliferation. New therapies targeting the restoration of CFTR function are rapidly evolving, which is crucial to enhancing patient quality of life. Various treatments being explored include mucociliary clearance modulators, anti-inflammatories, and anti-infective drugs, though this review primarily focuses on CFTR modulators and gene therapies.

Classification of CFTR Defects

The CFTR gene has over 2000 variants, with at least 360 classified as CF-causing mutations, impacting therapeutic strategies. The diverse molecular and clinical effects of these mutations present significant challenges in developing effective treatments. Classification assists high-throughput screening and drug development but remains imperfect due to genotype variability affecting responses to therapy. The categorization of CFTR mutations spans seven classes, with each class representing different types of defects from class I (nonsense mutations) to class VII (modified function).

Details of Mutation Classes

Class I mutations result in no functional CFTR protein synthesis due to nonsense or frameshift mutations. Class II mutations lead to misfolded CFTR protein, such as F508del, which is the most prevalent globally. Class III mutations are gating defects where the CFTR protein reaches the apical membrane but is not properly activated, exemplified by the G551D mutation. Class IV mutations involve altered anion conductance due to structural anomalies in CFTR. Class V mutations are characterized by reduced expression of the CFTR protein at the membrane due to regulatory mutations. Class VI mutations show stable CFTR at the membrane but with rapid turnover, leading to lower protein density.

CFTR Modulators and First-Generation Therapies

Ivacaftor

Ivacaftor (Kalydeco) was the first CFTR modulator approved for patients over six years old with specific mutations. Clinical trials have demonstrated significant improvements in lung function and a reduction in exacerbations, particularly for mutations like G551D. Registry studies show its long-term efficacy by enhancing airway microbiology and decreasing hospitalizations; however, it remains limited in broader applications for all CFTR mutations.

Potentiators and Correctors

There is a need for combination therapies, especially for the most frequent CF mutation, F508del, which does not respond adequately to monotherapy. Combination therapies such as Lumacaftor-Ivacaftor (Orkambi) provide modest clinical improvements for F508del homozygous patients but raise safety concerns regarding liver enzyme induction. Tezacaftor-Ivacaftor (Symdeko) offers a better pharmacokinetic profile and fewer adverse effects compared to Lumacaftor, showing some efficacy in homozygous and heterozygous patients afflicted with F508del.

Next-Generation Therapies

Elexacaftor-Tezacaftor-Ivacaftor (Trikafta) is a breakthrough therapy that combines elexacaftor and tezacaftor alongside ivacaftor, significantly increasing CFTR protein function and improving lung function in clinical trials. This reflects an important advancement in the management of CF.

Ongoing Research and Future Directions

Continued development focuses on identifying personalized treatments and improving access to these therapies for a wider population suffering from CF. Efforts aim to integrate genetic and environmental factors to create more tailored therapies. Other novel agents in development include CFTR amplifiers, pre-termination codon agents targeting rare mutations, and CFTR stabilizers aimed at maintaining CFTR protein integrity. Additionally, gene therapy approaches are being explored with various delivery systems, including nanoparticles and viral vectors. Theranostics initiatives for personalized medicine seek to accurately predict therapeutic responses, enhancing treatment efficacy for diverse CFTR mutations.

Conclusion

The landscape for CF therapies has evolved significantly, holding high potential for improved outcomes in approximately 90% of patients. However, challenges remain regarding equitable access to therapies, particularly among underrepresented populations, underscoring the imperative for ongoing innovation and dedication in CF research and care.